Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

News Conference News ACC 2019

Final MOMENTUM 3 Results Secure Superiority Claim for HeartMate 3 LVAD

Shelley Wood

March 22, 2019

News Conference News ACC 2019

COAPT Echo Substudy in HF Patients With Mitral Regurgitation Offers New Answers, and More Questions

Shelley Wood

March 17, 2019

News Conference News ACC 2018

Newest HeartMate 3 LV Assist Device Slashes Thrombosis, Reoperation Rates in Advanced HF: MOMENTUM 3

Shelley Wood

March 16, 2018

News Conference News ACC 2016

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

Shelley Wood

April 08, 2016

News Conference News ACC 2016

‘Enhanced’ Multicellular Stem Cell Therapy Improves Clinical Outcomes in Heart Failure: ixCELL-DCM Study

Michael O'Riordan

April 04, 2016

News Conference News ACC 2014

Intramyocardial Injection of Stem Cells Shows Promise for Severe Ischemic Heart Failure

Yael L. Maxwell

March 31, 2014

Presentation ACC 2012

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Ischemic Heart Failure: The FOCUS-CCTRN Trial

Presenter: Emerson C. Perin

March 25, 2012

Advertisement

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

‘Enormous’ QoL Improvements With Mavacamten in HCM

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Final MOMENTUM 3 Results Secure Superiority Claim for HeartMate 3 LVAD

COAPT Echo Substudy in HF Patients With Mitral Regurgitation Offers New Answers, and More Questions

Newest HeartMate 3 LV Assist Device Slashes Thrombosis, Reoperation Rates in Advanced HF: MOMENTUM 3

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

‘Enhanced’ Multicellular Stem Cell Therapy Improves Clinical Outcomes in Heart Failure: ixCELL-DCM Study

Intramyocardial Injection of Stem Cells Shows Promise for Severe Ischemic Heart Failure

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Ischemic Heart Failure: The FOCUS-CCTRN Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content